非布司他治疗痛风疗效如何？

It is a selective inhibitor of non-purinic xanthine oxidase/xanthine dehydrogenase and is the first anti-gout drug that inhibits uric acid synthesis. So, how effective is febuxostat in treating gout?

在一项临床试验进行了非布司他（80和120mg/d）和别嘌醇（300mg/d）的疗效。 A 1-year study of 760 patients showed that compared with the allopurinol group, more patients in the this product group achieved the main trial efficacy indicator - the sUA concentration measured in the last 3 months was less than 60 mg/L (all subjects were gout patients, and the sUA concentration before the trial was above 80 mg/L); during treatment After 52 weeks of treatment, this product failed to significantly reduce the area of tophi (tophi is an aggregation of urate crystals unique to gout), but the effect was more obvious in the high-dose group in the early stages of the trial; in each treatment group, patients with sUA concentrations reaching the target (<60mg/L) were less likely to have gout attacks again, and their tophi area was more significantly reduced!

Advantages of Febuxostat:

Febuxostat has fewer side effects.

非布司他和别嘌醇虽然都是抑制尿酸合成药物，药理作用却有一定差别。 Simply put, febuxostat inhibits uric acid synthesis more specifically, while allopurinol, in addition to inhibiting uric acid synthesis, also affects the metabolism of other organs in the human body, leading to more side effects.

Febuxostat is suitable for a wider range of people.

Febuxostat is mainly metabolized in the liver. 49% of the metabolized inactive substances are excreted through the kidneys, 45% through feces, and some through bile. It is excreted through multiple pathways, so it is completely suitable for patients with mild or moderate renal failure and patients with mild or moderate hepatic insufficiency.

The remarkable efficacy of Febuxostat has been well received by many gout patients; however, after all, gout requires long-term treatment, so choosing a generic version can further reduce the cost of drug use for patients!